A new approach to reducing the immunological side effects of gene therapy exploits microRNA to knock down transgene expression in immune cells.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles
Nature Communications Open Access 03 December 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Bob Crimi
References
Brown, B.D. et al. Nat. Med. 12, 585–91 (2006).
Stripecke, R. et al. Gene Ther. 6, 1305–1312 (1999).
Nathwani, A.C. et al. Blood 107, 2653–2661 (2006).
Follenzi, A. et al. Blood 103, 3700–3709 (2004).
Bartel, D.P. Cell 116, 281–297 (2004).
He, L. & Hannon, G.J. Nat. Rev. Genet. 5, 522–531 (2004).
Dorsett, Y. & Tuschl, T. Nat. Rev. Drug Discov. 3, 318–329 (2004).
Griffiths-Jones, S. et al. Nucleic Acids Res. 34, D140–D144 (2006).
Chen, C.Z. et al. Science 303, 83–86 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Qasim, W., Thrasher, A. RISC control for gene therapy. Nat Biotechnol 24, 661–662 (2006). https://doi.org/10.1038/nbt0606-661
Issue date:
DOI: https://doi.org/10.1038/nbt0606-661
This article is cited by
-
Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles
Nature Communications (2014)
